Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 6.84
NBS's Cash to Debt is ranked higher than
69% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 68.42 vs. NBS: 6.84 )
NBS' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 6.84

Equity to Asset 0.59
NBS's Equity to Asset is ranked higher than
67% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. NBS: 0.59 )
NBS' s 10-Year Equity to Asset Range
Min: -40.98   Max: 0.92
Current: 0.59

-40.98
0.92
F-Score: 4
Z-Score: -1.34
M-Score: -0.82
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -250.95
NBS's Operating margin (%) is ranked higher than
63% of the 794 Companies
in the Global Biotechnology industry.

( Industry Median: -68.50 vs. NBS: -250.95 )
NBS' s 10-Year Operating margin (%) Range
Min: -10991.67   Max: -27.04
Current: -250.95

-10991.67
-27.04
Net-margin (%) -265.76
NBS's Net-margin (%) is ranked higher than
62% of the 794 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. NBS: -265.76 )
NBS' s 10-Year Net-margin (%) Range
Min: -13154.35   Max: -33.38
Current: -265.76

-13154.35
-33.38
ROE (%) -62.33
NBS's ROE (%) is ranked higher than
59% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. NBS: -62.33 )
NBS' s 10-Year ROE (%) Range
Min: -2072.26   Max: -28.35
Current: -62.33

-2072.26
-28.35
ROA (%) -43.40
NBS's ROA (%) is ranked higher than
62% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -17.51 vs. NBS: -43.40 )
NBS' s 10-Year ROA (%) Range
Min: -2220   Max: 1258.09
Current: -43.4

-2220
1258.09
ROC (Joel Greenblatt) (%) -286.59
NBS's ROC (Joel Greenblatt) (%) is ranked higher than
70% of the 876 Companies
in the Global Biotechnology industry.

( Industry Median: -201.33 vs. NBS: -286.59 )
NBS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -160100   Max: -39.31
Current: -286.59

-160100
-39.31
Revenue Growth (%) -62.40
NBS's Revenue Growth (%) is ranked higher than
55% of the 638 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. NBS: -62.40 )
NBS' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 290.2
Current: -62.4

0
290.2
EBITDA Growth (%) -11.10
NBS's EBITDA Growth (%) is ranked higher than
72% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. NBS: -11.10 )
NBS' s 10-Year EBITDA Growth (%) Range
Min: -56.8   Max: 14.1
Current: -11.1

-56.8
14.1
EPS Growth (%) -25.30
NBS's EPS Growth (%) is ranked higher than
66% of the 636 Companies
in the Global Biotechnology industry.

( Industry Median: -12.20 vs. NBS: -25.30 )
NBS' s 10-Year EPS Growth (%) Range
Min: -52.7   Max: 9.6
Current: -25.3

-52.7
9.6
» NBS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

NBS Guru Trades in

NBS Guru Trades in

Q3 2013

NBS Guru Trades in Q3 2013

Jim Simons 30,037 sh (New)
» More
Q4 2013

NBS Guru Trades in Q4 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NBS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.70
NBS's P/B is ranked higher than
81% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. NBS: 2.70 )
NBS' s 10-Year P/B Range
Min: 0.59   Max: 150
Current: 2.7

0.59
150
P/S 9.20
NBS's P/S is ranked higher than
64% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 17.18 vs. NBS: 9.20 )
NBS' s 10-Year P/S Range
Min: 0.42   Max: 360.71
Current: 9.2

0.42
360.71
Current Ratio 3.43
NBS's Current Ratio is ranked higher than
69% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.97 vs. NBS: 3.43 )
NBS' s 10-Year Current Ratio Range
Min: 0.01   Max: 12.92
Current: 3.43

0.01
12.92
Quick Ratio 3.26
NBS's Quick Ratio is ranked higher than
70% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NBS: 3.26 )
NBS' s 10-Year Quick Ratio Range
Min: 0.01   Max: 12.92
Current: 3.26

0.01
12.92

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.40
NBS's Dividend Yield is ranked lower than
83% of the 168 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. NBS: 0.40 )
NBS' s 10-Year Dividend Yield Range
Min: 0.38   Max: 2.4
Current: 0.4

0.38
2.4
Yield on cost (5-Year) 0.40
NBS's Yield on cost (5-Year) is ranked lower than
80% of the 174 Companies
in the Global Biotechnology industry.

( Industry Median: 1.20 vs. NBS: 0.40 )
NBS' s 10-Year Yield on cost (5-Year) Range
Min: 0.38   Max: 2.4
Current: 0.4

0.38
2.4
Share Buyback Rate -58.30
NBS's Share Buyback Rate is ranked higher than
57% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. NBS: -58.30 )
NBS' s 10-Year Share Buyback Rate Range
Min: -14.5   Max: -150.6
Current: -58.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 80.70
NBS's Price/Tangible Book is ranked lower than
67% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 8.60 vs. NBS: 80.70 )
NBS' s 10-Year Price/Tangible Book Range
Min: 2.05   Max: 94.57
Current: 80.7

2.05
94.57
Price/Median PS Value 0.40
NBS's Price/Median PS Value is ranked higher than
92% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. NBS: 0.40 )
NBS' s 10-Year Price/Median PS Value Range
Min: 0.02   Max: 14.51
Current: 0.4

0.02
14.51
Earnings Yield (Greenblatt) 9.10
NBS's Earnings Yield (Greenblatt) is ranked higher than
72% of the 463 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. NBS: 9.10 )
NBS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 92.2
Current: 9.1

0.6
92.2
Forward Rate of Return (Yacktman) -106.96
NBS's Forward Rate of Return (Yacktman) is ranked higher than
56% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. NBS: -106.96 )
NBS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 14.7   Max: 15.5
Current: -106.96

14.7
15.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:8NE1.Germany
Neostem, Inc., was incorporated under the laws of the State of Delaware in September 1980 under the name Fidelity Medical Services, Inc. It is involved in an emerging cellular therapy industry. Cellular therapy addresses the process by which new cells are introduced into a tissue to prevent or treat disease, or regenerate damaged or aged tissue, and comprises a separate therapeutic technology platform in addition to three pillars of healthcare namely pharmaceuticals, biologics and medical devices. Its business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization (CDMO) providing services to others in the regenerative medicine industry. The Company's segments include Cell Therapy-United States; Regenerative Medicine-China and Pharmaceutical Manufacturing-China. The two largest third party CDMO competitors focused in the field of cell therapy are Lonza Group Ltd. and WuXi AppTec. The Company is subject to various governmental regulatory authorities, as well as private accreditation organizations, oversee and monitor the activities of individuals and businesses engaged in the development, manufacture and delivery of health care products and services.
» More Articles for NBS

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
NeoStem to Present at the Swedish-American Life Science Summit 2014 Aug 20 2014
NeoStem to Present at the Swedish-American Life Science Summit 2014 Aug 20 2014
NEOSTEM, INC. Financials Aug 19 2014
NEOSTEM, INC. Files SEC form 8-K, Results of Operations and Financial Condition Aug 07 2014
NeoStem Announces Second Quarter 2014 Financial Results and Provides Business Update Aug 07 2014
NeoStem Announces Second Quarter 2014 Financial Results and Provides Business Update Aug 07 2014
NEOSTEM, INC. Files SEC form 10-Q, Quarterly Report Aug 07 2014
Increase Company Value Through Mergers, Acquisitions Jul 14 2014
NeoStem Awarded 2014 Cell Therapeutics Technology Leadership Award from Frost & Sullivan Jul 14 2014
NeoStem Awarded 2014 Cell Therapeutics Technology Leadership Award from Frost & Sullivan Jul 14 2014
NeoStem, Inc. – "Insider Buying" Jul 08 2014
RedChip Announces Schedule for Its July 16-17 Global Online CEO Conference Jul 08 2014
NeoStem Appoints Steven M. Klosk to Board of Directors Jul 08 2014
NEOSTEM, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD... Jul 08 2014
NeoStem Appoints Steven M. Klosk to Board of Directors Jul 08 2014
NeoStem's Cancer Immunotherapy Experts to Present at Novel Cancer Therapeutics Summit 2014 Jun 30 2014
NeoStem, Inc. "Cancer Treatment that Doesn't Make You Sick" Jun 25 2014
NeoStem Set to Join Multiple Russell Indexes Jun 23 2014
NeoStem presents results for Phase 1 study of autologous Treg immunotherapy Jun 16 2014
NeoStem Announces UCSF Presentation of Phase 1 Results for T Regulatory Cell Immunotherapy for Type... Jun 16 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide